Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
MONDAY, April 22, 2024 -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 22, 2024 Category: Pharmaceuticals Source Type: news
Alectinib Approved for ALK-Positive Adjuvant NSCLC Alectinib Approved for ALK-Positive Adjuvant NSCLC
The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC
(MedPage Today) -- The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK inhibitor.
The approval stipulates use of alectinib... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 19, 2024 Category: Hematology Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Media News - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 18, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
CT-based deep learning identifies patients at further lung cancer risk
A CT-based deep learning model can identify individuals with clinical stage IA non–small cell lung cancer (NSCLC) at high risk of further disease, researchers have found.
A model developed by a team led by Kwon Joong Na, MD, of Seoul National University Hospital and College of Medicine in South Korea demonstrated an area under the receiver operating curve (AUC) of 0.86 for predicting recurrence of disease at two-years post procedure. The group's results were published April 16 in Radiology.
Lobectomy has traditionally been the standard approach for treating early-stage lung cancer, but new research has suggested that s...
Source: AuntMinnie.com Headlines - April 16, 2024 Category: Radiology Authors: Kate Madden Yee Tags: CT Artificial Intelligence Source Type: news
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
FRIDAY, April 12, 2024 -- Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2024 Category: Pharmaceuticals Source Type: news
It Takes a Village: Treating Patients for NSCLC Brain Mets It Takes a Village: Treating Patients for NSCLC Brain Mets
Treatment decisions for patients with NSCLC metastasized to the brain should involve a multidisciplinary team, considering factors such as immunotherapy efficacy and optimal treatment sequences.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 2, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Thursday, Bristol Myers Squibb & Co BMY announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE trial program of Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease. The study did not meet its…#zeposia #ozanimod #crohn #yellowstone #bristolmyerssquibb #nsclc #krasg12c #krazati #orr #fda (Source: Reuters: Health)
Source: Reuters: Health - April 1, 2024 Category: Consumer Health News Source Type: news
Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC
Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC? Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?
A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Continued Benefit, More Toxicity With Osimertinib-Chemo Continued Benefit, More Toxicity With Osimertinib-Chemo
Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
JCO ® Precision Oncology (JCO PO) Publishes Study Demonstrating Clinical Validity and Utility of OncoHost's PROphet® NSCLC Test
Hope for metastatic patients as PROphet® blood test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors BINYAMINA, Israel and CARY, N.C., March 21, 2024 /PRNewswire/ -- OncoHost, a technology company... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 21, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
As great of an investment as Eli Lilly (NYSE: LLY) is during the age of Zepbound, its newest and hottest weight-loss drug, there are many other magnificent opportunities out there right now, and it'd be a disservice to your portfolio to ignore them entirely. Take Iovance Biotherapeutics (NASDAQ:…#elililly #lly #zepbound #iovance #fda #nsclc #atc #alexcarchidi #motleyfool #forgetelililly (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2024 Category: Consumer Health News Source Type: news
